Heart Failure Clinical Trials Network

在这项提案中，埃默里大学的心脏病学部寻求成为一个地区性临床中心 (RCC)在NHLBI的心力衰竭(HF)临床研究网络中，一个具有活动HF的中心网络 对产生和促进循证心衰实践感兴趣的方案。在这里，我们描述我们的高频 以及相关计划、合作者以及相关的临床和研究计划和机构，我们的 研究和其他成就，以及我们的教职员工和关键人员；我们还提供我们的 机构和个人在心力衰竭临床试验方面的专业知识，以及获取相关信息的文档 患者群体，包括妇女和少数民族，非常多的心力衰竭患者，以及 在拟议的埃默里RCC中进行多学科合作。我们相信埃默里大学的基础设施和 调查员已做好充分准备，能够实现网络的主要和次要目标。如果选择为 RCC，埃默里团队将勤奋工作，以实现网络的各种目标。我们还寻求 制定和实施临床研究技能发展核心，以协助新的研究人员 培养他们的研究技能，从而利用网络和 建立在心血管医学领域训练有素的临床研究人员的核心上，专注于心力衰竭。作为一种 为了表明我们有能力构思、设计和进行临床试验，我们还提出了一种随机、 安慰剂对照临床试验(一氧化氮诱导的急性心力衰竭血管扩张评估-新型心力衰竭) 口服联苯肼联合硝酸异山梨酯治疗慢性阻塞性肺疾病的疗效评价 因收缩功能障碍入院的急性失代偿性心衰(AHDF)。这种疗法与 根据观察数据，血流动力学方面的好处可以改善ADHF的预后。埃默里 大学长期致力于多样性，亚特兰大的人口结构提供了一个 丰富的环境，研究不同患者群体在治疗方面的异同。我们 因此，建议进行一项临床试验，以评估当今心力衰竭医学面临的一个关键临床问题，即H- ADHF患者的ISDN，其益处和作用机制，以及黑人与非黑人心衰患者的预后。

In this proposal, the Division of Cardiology at Emory University seeks to become a Regional Clinical Center (RCC) within NHLBI's Heart Failure (HF) Clinical Research Network, a network of centers with active HF programs interested in generating and promoting evidence-based HF practice. Herein, we describe our HF and related programs, collaborators, and related clinical and research programs and institutions, our research and other accomplishments, and our faculty and key personnel; we also provide evidence of our institutional and individual expertise in clinical trials in HF, as well as documentation of access to relevant patient populations including women and minorities, extraordinary volume of HF patients, and multidisciplinary collaboration in the proposed Emory RCC. We believe that the Emory University infrastructure and investigators are well-equipped to achieve the primary and secondary goals of the Network. If chosen as a RCC, the Emory team will work diligently to achieve the various aims for the Network. We also seek to develop and implement a Clinical Research Skills Development Core to assist new investigators in developing their research skills, thus taking advantage of the rich environment presented by the Network and build upon the core of well trained clinical researchers within cardiovascular medicine focused on HF. As an indication of our ability to conceive, design, and conduct clinical trials, we also propose a randomized, placebo-controlled clinical trial (Nitric Oxide induced Vasodilation Evaluation in acute HF - NOVEL-HF) to evaluate the efficacy of the oral combination of hydralazine plus isosorbide dinitrate (H-ISDN) in patients with HF due to systolic dysfunction admitted with acute decompensated HF (AHDF). This therapy is associated with hemodynamic benefits that could improve outcomes in ADHF based on observational data. Emory University has a longstanding commitment to diversity and the population mix in the city of Atlanta offers a rich environment to study the similarities and differences in treatment among diverse patient groups. We therefore propose a clinical trial to assess a key clinical question facing HF medicine today, i.e. the role of H- ISDN in ADHF, its benefits and mechanisms of action, and outcomes in black versus non-black HF patients.